Efficacy of epigallocatechin gallate (EGCG) and its underlying mechanism in preventing bisphenol-A-induced metabolic disorders in mice

To investigate the efficacy of epigallocatechin gallate (EGCG) and its underlying mechanism in preventing bisphenol-A-induced metabolic disorders, in this study, a mice model of metabolic disorders induced by BPA was developed to investigate the efficacy and mechanism of EGCG using microbiomes and metabolomics. The results showed that EGCG reduced body weight, liver weight ratio, and triglyceride and total cholesterol levels in mice by decreasing the mRNA expression of genes related to fatty acid synthesis (Elov16) and cholesterol synthesis (CYP4A14) and increasing the mRNA expression of genes related to fatty acid oxidation (Lss) and cholesterol metabolism (Cyp7a1). In addition, EGCG normalized BPA-induced intestinal microbial dysbiosis. Metabolic pathway analysis showed that low-dose EGCG was more effective than high-dose EGCG at affecting the biosynthesis of L-cysteine, glycerophosphorylcholine, and palmitoleic acid. These results provide supporting data and a theoretical basis for the risk assessment of BPA and the utilization of EGCG. Bisphenol A (BPA), an endocrine disruptor, affects glucose tolerance, cholesterol biosynthesis, and fatty acid synthesis, leading to lipid metabolism disorders. The active ingredient epigallocatechin gallate (EGCG) in green tea could alleviate metabolic disorders induced by improper diet. However, there are limited studies on the role of EGCG in preventing EDCs induced obesity. In this work, we revealed efficacy of EGCG and its underlying mechanism in preventing bisphenol-A-induced metabolic disorders. The research results provide supporting data and a theoretical basis for the risk assessment of BPA and the utilization of EGCG.